Canakinumab (Ilaris) subcutaneous injection — Medical Necessity and Prior Authorization Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medical necessity and prior authorization criteria for canakinumab (Ilaris) subcutaneous injection administered by a healthcare professional for approved autoinflammatory and inflammatory indications, governing providers and members covered by Blue Cross NC.
For CAPS: Added required diagnostic confirmation by either genetic testing or presence of elevated inflammatory markers plus at least two CAPS-typical symptoms.
For TRAPS: Added required diagnostic confirmation by genetic testing; added requirement for chronic or recurrent disease (>6 flares per year) and submission of baseline CRP levels.
For HIDS/MKD: Combined criteria; added diagnostic confirmation by genetic testing or significantly elevated serum IgD, requirement for at least 3 febrile episodes in 6 months, and baseline CRP submission.
For FMF: Added required diagnostic confirmation by genetic testing, requirement for active disease (≥1 febrile episode per month), and baseline CRP submission.
For SJIA and AOSD: Allowed continuation of canakinumab for patients established on an FDA-approved biologic or systemic immunomodulator if they have had positive clinical benefit; added defined trial durations for conventional agents for AOSD to align with SJIA.
Coverage Criteria for Canakinumab (Ilaris)
Initial Therapy
Covered when ALL of the following are met for the requested indication (Initial Criteria for Approval):
Medical record documentation required as specified in indication branches
Indication-specific
- CAPS branch
- TRAPS branch
- HIDS/MKD branch
- FMF branch
- SJIA branch
- AOSD branch
- Gout branch
CAPS
CAPS branch (must meet ALL):
Medical record documentation required for genetic testing or labs and symptom history
TRAPS
TRAPS branch (must meet ALL):
Medical record documentation required for genetic testing and baseline CRP
HIDS / MKD
HIDS / MKD branch (must meet ALL):
Medical record documentation required for genetic testing or IgD level and febrile episode history and baseline CRP
FMF
FMF branch (must meet ALL):
Medical record documentation required for genetic testing, colchicine trial or intolerance, and baseline CRP
SJIA
SJIA branch (must meet ALL):
Medical record documentation required for trials, intolerance, or documentation of clinical benefit for established biologic/systemic immunomodulator use
AOSD
AOSD branch (must meet ALL):
Medical record documentation required for drug trials, intolerance, or documentation of clinical benefit for established biologic/systemic immunomodulator use
Gout flares
Gout flares branch (must meet ALL):
Duration of approval limited to 84 days for gout flares; medical record documentation required for prior trials and intolerance/contraindications
Continuation Therapy
Continuation Therapy (must meet ALL):
Medical record documentation required for prior approval, demonstration of clinical benefit, and intervals
The policy prohibits concurrent use of canakinumab with other biologic immunomodulator therapies. Canakinumab may not be used in combination with another biologic immunomodulator agent; prescribers must confirm the medication will be administered as monotherapy when required by the indication-specific criteria and document any existing biologic therapy status (e.g., established on an FDA‑approved biologic with documented benefit for continuation requests).
Requests that exceed the plan’s predefined maximum quantity or fail to meet indication‑specific or site‑of‑care requirements are considered not medically necessary. The prescriber must ensure the requested quantity does NOT exceed the maximum units allowed for the duration of approval and must follow the Site of Care rules for inpatient or outpatient administration for injection/infusion requests. Requests that do not meet these requirements may be denied.
Duration limits apply by indication: Gout flares — 84 days (12 weeks); All other indications — 365 days (1 year). Ensure the requested approval period and total units align with these limits to avoid non‑coverage.
Coding and Dosing Information
| J0638 | canakinumab, 1 mg (HCPCS) |
Prior Authorization & Documentation Requirements
Prior authorization required (HCPCS J0638)
Prior authorization is required for canakinumab (Ilaris) subcutaneous injection billed with HCPCS code J0638; requests must meet the applicable initial or continuation medical necessity criteria and must not exceed the policy maximum units for the approval duration.
- Covered HCPCS code: J0638 (canakinumab, 1 mg).
- Requested quantity must not exceed Maximum Units = 1,050 for the duration of approval.
- Requests must satisfy initial or continuation criteria in the policy.
Required trials of conventional agents
For specified indications the policy requires documented trials of conventional therapies with minimum durations (unless intolerant or contraindicated) prior to canakinumab approval.
- FMF: trial of colchicine for at least a 6-month trial or documented intolerance/contraindication to colchicine (medical record documentation required).
- Gout flares: trial and inadequate response or intolerance/contraindication to at least one NSAID AND trial/inadequate response or intolerance/contraindication to colchicine (medical record documentation required).
- SJIA: inadequate response to TWO drug classes which may include DMARDs (≥3 months), systemic corticosteroids (≥1 month), or NSAIDs (≥1 month) OR intolerance/contraindication to listed classes OR currently established on an FDA-approved biologic/systemic immunomodulator with documented clinical benefit.
Required supporting documentation
Medical record documentation must be submitted to support diagnostic confirmation, baseline inflammatory markers, prior therapy trials/intolerance, and clinical benefit for continuation requests.
- Genetic testing results when required (e.g., NLRP3/CIAS1 for CAPS, TNFRSF1A for TRAPS, MVK for HIDS/MKD, MEFV exon 10 for FMF) or alternative diagnostic lab confirmation (e.g., significantly elevated IgD).
- Baseline serum inflammatory markers (CRP and/or SAA) as specified per indication; baseline CRP documented for TRAPS, HIDS/MKD, FMF.
- Documentation of trials and failures or intolerance to prior therapies (e.g., colchicine, NSAIDs, methotrexate, DMARDs, corticosteroids) and evidence of clinical benefit for continuation requests.
Denial risk for criteria non‑adherence
Requests that do not meet the policy's initial or continuation medical necessity criteria, or that exceed maximum units or site-of-care rules, may be denied.
- Nonconformance with indication-specific criteria (e.g., missing genetic confirmation, inadequate trial durations, insufficient flare history) risks denial.
- Requests exceeding the maximum allowed units for the approval duration or not meeting site-of-care requirements may be considered not medically necessary and denied.
Background
Canakinumab (Ilaris) is a human monoclonal antibody that targets and neutralizes interleukin‑1 beta (IL‑1β), reducing inflammation driven by IL‑1β–mediated pathways. It is indicated for several autoinflammatory periodic fever syndromes and inflammatory conditions, including cryopyrin‑associated periodic syndromes, TRAPS, HIDS/MKD, familial Mediterranean fever, systemic juvenile idiopathic arthritis, adult‑onset Still’s disease, and for symptomatic treatment of gout flares when standard therapies are contraindicated, not tolerated, or ineffective. The policy aligns FDA‑labeled indications and dosing with medical necessity requirements and specifies documentation and monitoring (e.g., baseline inflammatory markers and genetic confirmation where required) for many indications.
Clinical Definitions Referenced in Criteria
Revision History and Policy Updates
Multiple July 2026 updates: CAPS now requires diagnostic confirmation by genetic testing or elevated inflammatory markers plus ≥2 CAPS-typical symptoms; TRAPS requires genetic testing confirmation, definition of chronic/recurrent disease (>6 flares/year) and baseline CRP submission; HIDS and MKD criteria combined with requirement for genetic testing or significantly elevated serum IgD, ≥3 febrile episodes in 6 months, and baseline CRP submission; FMF requires genetic testing confirmation, active disease (≥1 febrile episode/month), and baseline CRP submission; SJIA and AOSD criteria aligned to allow continuation for members established on an FDA‑approved biologic/systemic immunomodulator with documented clinical benefit and to align trial durations for conventional agents for AOSD with SJIA.
Site of Care medical necessity criteria updated to add additional bypass for patients with history of severe adverse events or conditions increasing risk for severe adverse events to align with Place of Service for Medical Infusions policy.
Adjusted maximum units to align with FDA labeling; other minor clarifying updates with no change to policy intent.
Added new indication for gout flares with corresponding criteria and dosing table updates.
Added Site of Care medical necessity criteria (policy notification given 8/2/2021).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.